Skip to main content

Advertisement

SpringerLink
Log in

Association of promoter methylation of ERα and ERβ with sporadic breast cancer—a study from North India

  • Research Article
  • Published:
Tumor Biology

Abstract

Methylations in estrogen receptor (ER) α and ERβ are known to be involved in the pathogenesis of breast cancer. Here, we explore the role of promoter methylation of estrogen receptors, ERα and ERβ, in sporadic breast cancer cases from a North Indian population. To this end, association between ERα and ERβ methylation status along with different clinicopathological parameters and its correlation with protein expression was examined. Four hundred eighty paired breast cancer tissue samples and adjacent normal controls from 240 sporadic breast cancer patients were included, and their clinical and demographic profiles were recorded. ERα and ERβ methylation was determined by methylation-specific polymerase (MSP) chain reaction. Our findings demonstrate that methylation of ERα and ERβ occurs in high frequency and appears to be a mechanism of gene silencing in our population. Furthermore, on performing stratified analysis, we observed strong associations between ERα/ERβ methylation and ER, PR, and HER2 status, tumor size, clinical stage, and triple negative tumors. Thus, our study not only highlights the role of ERα/ERβ methylation in breast cancer but also suggests the ERα/ERβ methylation pattern as a biomarker for assessing breast cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Breast cancer in developing countries. Lancet. 2009;374(9701):1567. doi:10.1016/S0140-6736(09)61930-9.

  3. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43. doi:10.1038/nrc2713.

    Article  CAS  PubMed  Google Scholar 

  4. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47. doi:10.1146/annurev-med-070909-182917.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6(5):213–8. doi:10.1186/bcr921.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64(1):423–8.

    Article  CAS  PubMed  Google Scholar 

  7. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994;54(10):2552–5.

    CAS  PubMed  Google Scholar 

  8. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, et al. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res. 1998;58(12):2515–9.

    CAS  PubMed  Google Scholar 

  9. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene. 2003;22(48):7600–6. doi:10.1038/sj.onc.1207100.

    Article  CAS  PubMed  Google Scholar 

  10. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer. 2005;12(4):903–16. doi:10.1677/erc.1.01088.

    Article  CAS  PubMed  Google Scholar 

  11. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 2004;64(22):8184–92. doi:10.1158/0008-5472.CAN-04-2045.

    Article  CAS  PubMed  Google Scholar 

  12. Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, et al. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. Cancer Epidemiol Biomarkers Prev. 2009;18(11):3036–43. doi:10.1158/1055-9965.EPI-09-0678.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Wei J, Han B, Mao XY, Wei MJ, Yao F, Jin F. Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients. Tumour Biol. 2012;33(2):413–20. doi:10.1007/s13277-011-0234-x.

    Article  CAS  PubMed  Google Scholar 

  14. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 2000;60(3):702–6.

    CAS  PubMed  Google Scholar 

  15. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000;60(12):3175–82.

    CAS  PubMed  Google Scholar 

  16. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004;164(6):2003–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Yap OW, Bhat G, Liu L, Tollefsbol TO. Epigenetic modifications of the estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res. 2009;29(1):139–44.

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Sasaki M, Kotcherguina L, Dharia A, Fujimoto S, Dahiya R. Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res. 2001;61(8):3262–6.

    CAS  PubMed  Google Scholar 

  19. Lai JC, Cheng YW, Chiou HL, Wu MF, Chen CY, Lee H. Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int J Cancer. 2005;117(6):974–80. doi:10.1002/ijc.21278.

    Article  CAS  PubMed  Google Scholar 

  20. Mori T, Martinez SR, O’Day SJ, Morton DL, Umetani N, Kitago M, et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 2006;66(13):6692–8. doi:10.1158/0008-5472.CAN-06-0801.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Horii J, Hiraoka S, Kato J, Saito S, Harada K, Fujita H, et al. Methylation of estrogen receptor 1 in colorectal adenomas is not age-dependent, but is correlated with K-ras mutation. Cancer Sci. 2009;100(6):1005–11. doi:10.1111/j.1349-7006.2009.01140.x.

    Article  CAS  PubMed  Google Scholar 

  22. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253–66. doi:10.1038/nrc1045.

    Article  CAS  PubMed  Google Scholar 

  23. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5(1):37–50. doi:10.1038/nrd1930.

    Article  CAS  PubMed  Google Scholar 

  24. Chattopadhyay S, Siddiqui S, Akhtar MS, Najm MZ, Deo SV, Shukla NK, et al. Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India. Tumour Biol. 2014. doi:10.1007/s13277-013-1594-1.

    Google Scholar 

  25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23(36):9067–72. doi:10.1200/JCO.2004.01.0454.

    Article  PubMed  Google Scholar 

  26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst. 2002;94(5):384–90.

    Article  CAS  PubMed  Google Scholar 

  28. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–31.

    Article  CAS  PubMed  Google Scholar 

  29. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol. 2002;197(2):155–62. doi:10.1002/path.1077.

    Article  CAS  PubMed  Google Scholar 

  30. Zhao L, Wang L, Jin F, Ma W, Ren J, Wen X, et al. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat. 2009;117(2):253–9. doi:10.1007/s10549-008-0192-1.

    Article  CAS  PubMed  Google Scholar 

  31. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci. 2007;81(4):280–7. doi:10.1016/j.lfs.2007.05.012.

    Article  CAS  PubMed  Google Scholar 

  32. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem. 2010;43(4–5):380–6. doi:10.1016/j.clinbiochem.2009.11.016.

    Article  CAS  PubMed  Google Scholar 

  33. Li S, Rong M, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett. 2006;237(2):272–80. doi:10.1016/j.canlet.2005.06.011.

    Article  CAS  PubMed  Google Scholar 

  34. Jing MX, Mao XY, Li C, Wei J, Liu C, Jin F. Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women. Tumour Biol. 2011;32(4):713–9. doi:10.1007/s13277-011-0172-7.

    Article  CAS  PubMed  Google Scholar 

  35. Prabhu JS, Wahi K, Korlimarla A, Correa M, Manjunath S, Raman N, et al. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumour Biol. 2012;33(2):315–23. doi:10.1007/s13277-012-0343-1.

    Article  CAS  PubMed  Google Scholar 

  36. Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol. 2009;52(2):171–4.

    Article  PubMed  Google Scholar 

  37. Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: a study of 798 tumours. Breast. 2000;9(5):267–70. doi:10.1054/brst.2000.0134. discussion 70.

    Article  CAS  PubMed  Google Scholar 

  38. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11(3):537–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Zhao L, Yu Z, Li Y, Wen X, Ma W, Wang L, et al. Clinical implications of ERbeta methylation on sporadic breast cancers in Chinese women. Med Oncol. 2012;29(3):1569–75. doi:10.1007/s12032-011-0107-6.

    Article  CAS  PubMed  Google Scholar 

  40. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol. 2012;19(9):3107–15. doi:10.1245/s10434-012-2323-5.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank all the participants for their support. SA Husain acknowledges the support provided by the University Grants Commission (UGC), Government of India, for research funds and S Chattopadhyay acknowledges the support of Council of Scientific and Industrial Research (CSIR), Government of India, for research fellowship.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Biotechnology, Jamia Millia Islamia, New Delhi, 110025, India

    Shilpi Chattopadhyay & Syed Akhtar Husain

  2. Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India

    S. V. S. Deo & N. K. Shukla

Authors
  1. Shilpi Chattopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. V. S. Deo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. K. Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Syed Akhtar Husain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed Akhtar Husain.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chattopadhyay, S., Deo, S.V.S., Shukla, N.K. et al. Association of promoter methylation of ERα and ERβ with sporadic breast cancer—a study from North India. Tumor Biol. 35, 7911–7919 (2014). https://doi.org/10.1007/s13277-014-2052-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2052-4

Keywords

Search

Navigation